David W. Traylor

Founded by Darren Caris in 2002, Caris & Co., Inc. is a broker/dealer headquartered in Del Mar, California. The firm is a subsidiary of B. Riley & Co. They offer research that is independent of their investment banking activities, as well as a full array of trading and execution services. Caris & Co.'s coverage includes large-, mid- and small-cap companies in the healthcare, technology, energy and consumer sectors. Their research is written for the longer-term investor with an investment horizon of at least 12 months. Caris & Co., Inc. is a member of the NASD and the SIPC.

Headwaters MB LLC provides investment banking services to entrepreneurs, owner and operators, and business-owning families. It offers strategic merger and acquisition advice, capital raising, and special situations advisory. The company was founded by Phil Seefried and Dave Maney in 2001 and is headquartered in Denver, CO.

Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO.

Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA.

Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany

BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.